Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Public ClinicalTrials.gov record NCT04602390. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo
Study identification
- NCT ID
- NCT04602390
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 34 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2020 (Actual)
- Primary completion
- Apr 23, 2024 (Actual)
- Completion
- Apr 23, 2024 (Actual)
- Last update posted
- May 31, 2025
2020 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| North Central Neurology | Cullman | Alabama | 35058 | — |
| Barrow Neurological Institute | Phoenix | Arizona | 85013 | — |
| UC Health Neurosciences Center | Aurora | Colorado | 80045 | — |
| Aqualane Clinical Research | Naples | Florida | 34105 | — |
| University of South Florida - Neurology | Tampa | Florida | 33612 | — |
| University of Kansas Lander Center on Aging/ Neurology | Kansas City | Kansas | 66103 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Jefferson University Hospitals | Philadelphia | Pennsylvania | 19107 | — |
| Midlands Neurology & Pain Associates PA | Columbia | South Carolina | 29205 | — |
| Advanced Neurosciences Institute | Franklin | Tennessee | 37064 | — |
| University of Texas Southwestern | Dallas | Texas | 75390 | — |
| University of Texas Health Science Center | Houston | Texas | 77030 | — |
| MS Center of Greater Washington | Vienna | Virginia | 22180 | — |
| MultiCare Health System | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04602390, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 31, 2025 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04602390 live on ClinicalTrials.gov.